Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: Clinical and economic considerations

International Journal of Women's Health

Volumn 6, Issue 1, 2014, Pages 509-521

  Lamond, Nathan W D ^a   Younis, Tallal ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Clinical trials; Drug development; HER2 neu; Novel therapies; Targeted anticancer therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIRUBICIN; FLUOROURACIL; PERTUZUMAB; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BINDING AFFINITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIMERIZATION; DRUG APPROVAL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEBRILE NEUTROPENIA; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ISLET CELL CARCINOMA; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; REVIEW; TREATMENT DURATION; TUMOR GROWTH;

EID: 84901442854     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S47357     Document Type: Review

References (73)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.
5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320-368.
7. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
9. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-4274.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
11. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34):5685-5692.
12. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25): 3366-3373.
13. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
14. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317-328.
15. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
16. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3-S8.
17. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513-516.
18. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16(10):5276-5287.
19. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996;15(10):2452-2467.
20. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100(15):8933-8938.
21. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55(6): 717-727.
22. Baselga J. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell. 2002;2(2):93-95.
23. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127-137.
24. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343-2346.
25. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878-5887.
26. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330-9336.
27. Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(7):1131-1137.
28. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23(11):2534-2543.
29. Attard G, Kitzen J, Blagden SP, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer. 2007;97(10):1338-1343.
30. Albanell J, Montagut C, Jones ET, et al. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2008;14(9):2726-2731.
31. Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol. 2009;39(4): 260-266.
32. Miller K, Gianni L, Andre F. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). J Clin Oncol. 2010;28(Suppl 15):1012.
33. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006;23(6):1275-1284.
34. Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res. 2008;14(9):2710-2716.
35. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138-1144.
36. Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594-1600.
37. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2): 109-119.
38. Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461-471.
39. Cortés J, Baselga J, Im YH, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013;24(10):2630-2635.
40. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974-986.
41. Eton DT, Cella D, Yost KJ, et al. A combination of distribution-and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57(9):898-910.
42. European Medicines Agency. Perjeta (pertuzumab). 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002547/human_med_001628.jsp&mid=WC0b01ac058001d124. Accessed October 7, 2013.
43. Health Canada. Summary basis of decision (SBD) for Perjeta. 2013. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2013_perjeta_158419-eng.php. Accessed October 7, 2013.
44. Traynor K. FDA approves pertuzumab for breast cancer. Am J Health Syst Pharm. 2012;69(14):1178.
45. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
46. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-2284.
47. US Food and Drug Administration. Approved drugs: pertuzumab injection. 2013. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm370449.htm. Accessed January 16, 2014.
48. Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18(3):257-264.
49. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. 2012;23(3):791-800.
50. Genentech. An Observational Study of Pregnancy and Pregnancy Outcomes in Women with Breast Cancer Treated with Herceptin, Perjeta in Combination with Herceptin, or Kadcyla During Pregnancy or Within 6 Months Prior to Conception (MotHER). Available from: http://clinicaltrials.gov/show/NCT00833963. NLM identifier: NCT00833963. Accessed September 24, 2013.
51. SOLTI Breast Cancer Research Group. Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER Heart). Available from: http://clinicaltrials.gov/show/NCT01669239. NLM identifier: NCT01669239. Accessed October 5, 2013.
52. Dana-Farber Cancer Institute. Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for BrCa. Available from: http://clinicaltrials.gov/show/NCT01796197. NLM identifier: NCT01796197. Accessed October 5, 2013.
53. Hoffmann-La Roche. A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients with HER2-Positive Primary Breast Cancer. Available from: http://clinicaltrials.gov/show/NCT01358877. NLM identifier: NCT01358877. Accessed September 18, 2013.
54. Memorial Sloan-Kettering Cancer Center. Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer. Available from: http://clinicaltrials.gov/show/NCT01276041. NLM identifier: NCT01276041. Accessed October 5, 2013.
55. Hoffmann-La Roche. A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Vinorelbine in First Line in Patients with Metastatic or Locally Advanced HER2-Positive Breast Cancer. Available from: http://clinicaltrials.gov/show/NCT01565083. NLM identifier: NCT01565083. Accessed September 22, 2013.
56. Hoffmann-La Roche. A Study of Pertuzumab in Combination with Trastuzumab Plus an Aromatase Inhibitor in Patients with Hormone Receptor-Positive, Metastatic HER2-Positive Breast Cancer. Available from: http://clinicaltrials.gov/show/NCT01491737. NLM identifier: NCT01491737. Accessed September 22, 2013.
57. Hoffmann-La Roche. A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients with Metastatic Breast Cancer (MARIANNE). Available from: http://clinicaltrials.gov/show/NCT01120184. NLM identifier: NCT01120184. Accessed September 18, 2013.
58. City of Hope Medical Center. Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER2-Positive Metastatic Breast Cancer. Available from: http://clinicaltrials.gov/show/NCT01730833. NLM identifier: NCT01730833. Accessed October 5, 2013.
59. Hoffmann-La Roche. A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and a Taxane in First-Line Treatment in Patients with HER2-Positive Advanced Breast Cancer (PERUSE). Available from: http://clinicaltrials.gov/show/NCT01572038. NLM identifier: NCT01572038. Accessed October 5, 2013.
60. Hoffmann-La Roche. HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients with Her2-Positive Advanced Breast Cancer after Adjuvant Herceptin Therapy. Available from: http://clinicaltrials.gov/show/NCT01777958. NLM identifier: NCT01777958. Accessed October 5, 2013.
61. European Organisation for Research and Treatment of Cancer. Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1. Available from: http://clinicaltrials.gov/show/NCT01597414. NLM identifier: NCT01597414. Accessed October 5, 2013.
62. Hoffmann-La Roche. A Study of a Combination of Trastuzumab and Capecitabine with or Without Pertuzumab in Patients with HER2-Positive Metastatic Breast Cancer (PHEREXA). Available from: http://clinicaltrials.gov/show/NCT01026142. NLM identifier: NCT01026142. Accessed September 22, 2013.
63. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676-3685.
64. Chambers JD, Lord J, Cohen JT, Neumann PJ, Buxton MJ. Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures. Value Health. 2013;16(4):629-638.
65. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060-2065.
66. Pan-Canadian Oncology Drug Review. Perjeta-Herceptin combo pack for MBC-details. 2013. Available from: http://www.pcodr.ca/wcpc/portal/Home/FindaReview/PerjetaHerceptinMBC?afrLoop=2304129379749000&_afrWindowMode=0&_adf.ctrl-state=fgpie73cf_134. Accessed September 20, 2013.
67. National Institute for Health and Care Excellence. Breast cancer (HER2 positive, metastatic)-pertuzumab (with trastuzumab and docetaxel) [ID523]. Available from: http://guidance.nice.org.uk/index.jsp?action=byId&o=13815. Accessed September 20, 2013.
68. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-342.
69. Mason H, Baker R, Donaldson C. Willingness to pay for a QALY: past, present and future. Expert Rev Pharmacoecon Outcomes Res. 2008;8(6):575-582.
70. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235-251.
71. Breast cancer (HER2 positive, metastatic)-pertuzumab (with trastuzumab and docetaxel): appraisal consultation document. Natl Inst Health Care Excell. Available at: http://guidance.nice.org.uk/TAG/322/Consultation/DraftGuidance. Accessed September 24, 2013.
72. Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28(7):1215-1223.
73. Şendur MAN, Aksoy S, Zengin N. Pertuzumab plus trastuzumab in metastatic breast cancer. N Engl J Med. 2012;366(14):1348; author reply 1349-1350.